| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8399514 | BIOGEN INC | Treatment for multiple sclerosis |
Feb, 2028
(4 years from now) | |
| US10994003 | BIOGEN INC | Dimethyl fumarate and vaccination regimens |
Mar, 2035
(11 years from now) | |
| US10555993 | BIOGEN INC | Dimethyl fumarate and vaccination regimens |
Mar, 2035
(11 years from now) | |
| US10391160 | BIOGEN INC | Dimethyl fumarate and vaccination regimens |
Mar, 2035
(11 years from now) | |
| US11007167 | BIOGEN INC | Methods of treating multiple sclerosis |
Nov, 2035
(12 years from now) | |
| US11246850 | BIOGEN INC | Methods of treating multiple sclerosis |
Nov, 2035
(12 years from now) | |
| US10959972 | BIOGEN INC | Methods of treating multiple sclerosis |
Nov, 2035
(12 years from now) | |
| US11129806 | BIOGEN INC | Methods of treating multiple sclerosis |
Nov, 2035
(12 years from now) | |
| US11007166 | BIOGEN INC | Methods of treating multiple sclerosis |
Nov, 2035
(12 years from now) | |
Tecfidera is owned by Biogen Inc.
Tecfidera contains Dimethyl Fumarate.
Tecfidera has a total of 9 drug patents out of which 0 drug patents have expired.
Tecfidera was authorised for market use on 27 March, 2013.
Tecfidera is available in capsule, delayed release;oral dosage forms.
Tecfidera can be used as method of treating relapsing forms of multiple sclerosis before and after administering an inactive vaccine, method of treating multiple sclerosis.
The generics of Tecfidera are possible to be released after 16 November, 2035.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M (M) | Feb 5, 2023 |
Drugs and Companies using DIMETHYL FUMARATE ingredient
Market Authorisation Date: 27 March, 2013
Treatment: Method of treating multiple sclerosis; Method of treating relapsing forms of multiple sclerosis before and after administering an inactive vaccine
Dosage: CAPSULE, DELAYED RELEASE;ORAL
TECFIDERA family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic